Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Oxford/AstraZeneca vaccine results face growing scrutiny

Oxford/AstraZeneca vaccine results face growing scrutiny

Share price drops as critics question claim vaccine could protect up to 90% of people
The Oxford University/AstraZeneca vaccine will undergo a new global trial as critics questioned the claim that it could protect up to 90% of people against coronavirus.

On Thursday Sir John Bell, Oxford’s regius professor of medicine and the UK government’s life sciences adviser, dismissed suggestions the previous trial had not been properly set up or reported. “We weren’t cooking this up as we went along,” he said, adding that he hoped the full, peer-reviewed data would be published in the Lancet medical journal at the weekend.

In spite of the public excitement generated by the announcement that a third vaccine had been successful – with particular promise for developing countries as it is relatively cheap and can be stored at fridge temperature – AstraZeneca’s share price dropped.

One analyst in the US wrote in an investor note that “we believe that this product will never be licensed in the US” and alleged the company had tried to “embellish” the results.

It comes after the headline figure for the vaccine’s overall efficacy was put at 70% – as announced by the company on Monday and discussed in a press briefing by the Oxford researchers. But a sub-set of fewer than 3,000 people in the UK was given a lower dose regime – originally by accident – where the efficacy rose to 90%. In most trial volunteers in Brazil and the UK, it was 62%.

Sir Mene Pangalos, AstraZeneca’s head of biopharmaceuticals R&D, has confirmed that the low-dose trial included nobody over the age of 55. This led to concerns that younger age may have been a factor – particularly relevant given that vulnerable elderly people are most at risk from Covid-19.

Researchers had no explanation for the 90% result in people given a half dose followed by a whole dose of the vaccine, instead of two whole doses in other arms of the trial.

On Thursday AstraZeneca said it would undertake a new global trial using the lower-dose regimen. The timeline for regulatory approval and rollout of the vaccine in the UK and Europe should not be affected.

Critics have also claimed the trials did not include enough ethnic diversity, gender and age balance to satisfy the US regulator, the Food and Drug Administration.

Defending the vaccine trials, Bell told a symposium run by the Faculty of Pharmaceutical Medicine: “[The] MHRA [Medicines and Healthcare Products Regulatory Authority] knew perfectly well what we were doing. They approved all the protocols.”

It had been widely accepted before any of the vaccine trials reported results that 60% efficacy would be enough for a licence and would be useful, he said. “We are well in excess of that. I can’t imagine any reason why regulators won’t accept that.”

America had not yet seen the full data, he said, which he hoped would be published in the Lancet at the weekend. “I think when they see the data, it will be a great deal easier to have these conversations.”

Scientists at Oxford and the company admitted they were surprised by the finding that a lower dosing regime got better results. Pangalos called it serendipity.

“It could be that by giving a small amount of the vaccine to start with and following up with a big amount, that’s a better way of kicking the immune system into action and giving us the strongest immune response and the most effective immune response,” said Prof Sarah Gilbert, who led the vaccine research at Oxford.

AstraZeneca’s CEO told Bloomberg it would begin an international trial using the lower-dose regimen, while previously it had been expected merely to add an arm to the existing trial in the US.

The move will be seen as a bid to satisfy the FDA and compete, if they do win a licence in the US, with Pfizer and Moderna which have both published data suggesting 95% efficacy.

“Now that we’ve found what looks like a better efficacy [in the half dose/full dose regime], we have to validate this, so we need to do an additional study,” CEO Pascal Soriot said on Thursday. The study would probably be global “but this one could be faster because we know the efficacy is high so we need a smaller number of patients”.

Peter Openshaw, professor of experimental medicine at Imperial College London, said more data would need to be collected if the low-dose arm of the trial included only under-55s.

“If this is true, it may mean we don’t have any information about this regimen in older adults,” he said. “We have to wait for the full data and to see how the regulators view the results of the phase 3 trials. The US and European regulators might possibly take a different view. All we have to go on is a limited data release.”

It was possible, he said, that the protection from the Oxford/AstraZeneca vaccine might be less than that from the Pfizer/BioNTech and Moderna vaccines, which were developed with a different technology based on RNA, “but we need to wait and see”.

Paul Hunter, professor in medicine at the University of East Anglia and an adviser on methodology to the World Health Organization, said he was always wary of sub-group analyses in trials.

“Most of the time when you get these incredibly good results in a sub-group analysis, you have to be incredibly careful about believing them,” he told the Guardian. There could be something about the smaller group that was not true of the larger group.

He was also worried by the suggestion the sub-group had nobody over 55. “I’m not saying this isn’t going to be a fantastic vaccine at the end of the day, but we need a lot better understanding of the data,” he said.

An AstraZeneca spokesperson said an independent data safety monitoring board ensures the safety and quality of the trials. “The studies were conducted to the highest standards,” it said in a statement. “More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection.”
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
The Personality Rights Challenge in India’s AI Era
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Study Finds No Safe Level of Alcohol for Dementia Risk
Trump Says Ukraine Can Fully Restore Borders with NATO Backing
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Germany Weighs Excluding France from Key European Fighter Jet Programme
Cyberattack Disrupts Check-in and Boarding Systems at Major European Airports
Björn Borg Breaks Silence: Memoir Reveals Addiction, Shame and Cancer Battle
When Extremism Hijacks Idealism: How the Baader-Meinhof Gang Emerged and Fell
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
Trump Orders $100,000 Fee on H-1B Visas and Launches ‘Gold Card’ Immigration Pathway
France’s Looming Budget Crisis and Political Fracture Raise Fears of Becoming Europe’s “Sick Man”
Three Russian MiG-31 Jets Breach Estonian Airspace in ‘Unprecedentedly Brazen’ NATO Incident
European manufacturers against ban on polluting cars: "The industry may collapse"
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
Christian Brueckner Released from German Prison after Serving Unrelated Sentence
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
The conservative right spreads westward: a huge achievement for 'Alternative for Germany' in local elections
Pope Leo Warns of Societal Crisis Over Mega-CEO Pay, Citing Tesla’s Proposed Trillion-Dollar Package
Poland Green-Lights NATO Deployment in Response to Major Russian Drone Incursion
U.S. and China Agree on Framework to Shift TikTok to American Ownership
Le Pen Tightens the Pressure on Macron as France Edges Toward Political Breakdown
Czech Republic signs €1.34 billion contract for Leopard 2A8 main battle tanks with delivery from 2028
Penske Media Sues Google Over “AI Overviews,” Claiming It Uses Journalism Without Consent and Destroys Traffic
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
One in Three Europeans Now Uses TikTok, According to the Chinese Tech Giant
Could AI Nursing Robots Help Healthcare Staffing Shortages?
NATO Deploys ‘Eastern Sentry’ After Russian Drones Violate Polish Airspace
The New Life of Novak Djokovic
German police raid AfD lawmaker’s offices in inquiry over Chinese payments
Volkswagen launches aggressive strategy to fend off Chinese challenge in Europe’s EV market
France Erupts in Mass ‘Block Everything’ Protests on New PM’s First Day
Poland Shoots Down Russian Drones in Airspace Violation During Ukraine Attack
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Macron Appoints Sébastien Lecornu as Prime Minister Amid Budget Crisis and Political Turmoil
Vatican hosts first Catholic LGBTQ pilgrimage
Apple Unveils iPhone 17 Series, iPhone Air, Apple Watch 11 and More at 'Awe Dropping' Event
France joins Eurozone’s ‘periphery’ as turmoil deepens, say investors
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
France, at an Impasse, Heads Toward Another Government Collapse
×